Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 16;12(2):196-205.
doi: 10.1093/ckj/sfy035. eCollection 2019 Apr.

Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study

Jan Menne  1 , Yahsou Delmas  2 , Fadi Fakhouri  3 , John F Kincaid  4 , Christoph Licht  5 , Enrico E Minetti  6 , Chris Mix  4 , François Provôt  7 , Eric Rondeau  8 , Neil S Sheerin  9 , Jimmy Wang  4 , Laurent E Weekers  10 , Larry A Greenbaum  11
Affiliations

Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study

Jan Menne et al. Clin Kidney J. .

Abstract

Background: Eculizumab, a terminal complement inhibitor, is approved for atypical haemolytic uraemic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

Methods: In five parent studies, eculizumab effectively prevented TMA and improved renal and haematologic outcomes in patients with aHUS; therefore, these patients could enrol in this long-term, prospective, observational and multicentre study. The primary endpoint was the TMA manifestation rate off and on eculizumab post-parent study. Post hoc analyses evaluated rates during labelled versus non-labelled dosing regimens, and in those with versus without identified complement abnormalities. Serious targeted treatment-emergent adverse events (TEAEs) were evaluated.

Results: Of 87 patients in the current study, 39 and 76 had off- and on-treatment periods, respectively; 17 (44%) with off periods reinitiated eculizumab. TMA manifestation rate per 100 patient-years was 19.9 off and 7.3 on treatment [hazard ratio (HR), 4.7; P = 0.0008]; rates were highest off treatment and lowest during labelled regimens. TMA manifestations with hospitalizations/serious AEs occurred more frequently off versus on treatment. TMA rates were higher among patients with identified complement abnormalities (HR, 4.5; P = 0.0082). Serious targeted TEAEs occurred at similar rates off and on treatment.

Conclusions: As expected, patients with aHUS have increased risk of TMA manifestations after discontinuation of eculizumab or in the setting of non-labelled eculizumab dosing. Collectively, results show that maintaining eculizumab treatment minimizes risk of TMA, particularly in patients with identified complement abnormalities. Future studies are needed to further characterize TMA and longer term outcomes on labelled or non-labelled eculizumab regimens and after discontinuation of treatment.

Keywords: atypical haemolytic uraemic syndrome; complement; discontinuation; eculizumab; observational study; thrombotic microangiopathy.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
Patient disposition.
See this image and copyright information in PMC

References

    1. Noris M, Remuzzi G.. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676–1687 - PubMed
    1. Noris M, Caprioli J, Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844–1859 - PMC - PubMed
    1. Fremeaux-Bacchi V, Fakhouri F, Garnier A. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554–562 - PMC - PubMed
    1. Noris M, Mescia F, Remuzzi G.. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622–633 - PubMed
    1. US Food and Drug Administration. Soliris (eculizumab) [Prescribing Information]. New Haven, CT: Alexion Pharmaceuticals, Inc, 2017